Literature DB >> 24850761

A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Andrew Yee1, Robert D Gildersleeve1, Shufang Gu2, Colin A Kretz1, Beth M McGee1, Keisha M Carr1, Steven W Pipe3, David Ginsburg4.   

Abstract

Plasma factor VIII (FVIII) and von Willebrand factor (VWF) circulate together as a complex. We identify VWF fragments sufficient for FVIII stabilization in vivo and show that hepatic expression of the VWF D'D3 domains (S764-P1247), either as a monomer or a dimer, is sufficient to raise FVIII levels in Vwf(-/-) mice from a baseline of ∼5% to 10%, to ∼50% to 100%. These results demonstrate that a fragment containing only ∼20% of the VWF sequence is sufficient to support FVIII stability in vivo. Expression of the VWF D'D3 fragment fused at its C terminus to the Fc segment of immunoglobulin G1 results in markedly enhanced survival in the circulation (t1/2 > 7 days), concomitant with elevated plasma FVIII levels (>25% at 7 days) in Vwf(-/-) mice. Although the VWF D'D3-Fc chimera also exhibits markedly prolonged survival when transfused into FVIII-deficient mice, the cotransfused FVIII is rapidly cleared. Kinetic binding studies show that VWF propeptide processing of VWF D'D3 fragments is required for optimal FVIII affinity. The reduced affinity of VWF D'D3 and VWF D'D3-Fc for FVIII suggests that the shortened FVIII survival in FVIII-deficient mice transfused with FVIII and VWF D'D3/D'D3-Fc is due to ineffective competition of these fragments with endogenous VWF for FVIII binding.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850761      PMCID: PMC4102715          DOI: 10.1182/blood-2013-11-540534

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Peptide affinity chromatography of human clotting factor VIII. Screening of the vWF-binding domain.

Authors:  R Necina; K Amatschek; E Schallaun; H Schwinn; D Josic; A Jungbauer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-09-11

2.  The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

Authors:  E L Saenko; D Scandella
Journal:  J Biol Chem       Date:  1997-07-18       Impact factor: 5.157

3.  von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies.

Authors:  U M Vischer; D D Wagner
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

4.  Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase.

Authors:  K L Mohlke; A A Purkayastha; R J Westrick; P L Smith; B Petryniak; J B Lowe; D Ginsburg
Journal:  Cell       Date:  1999-01-08       Impact factor: 41.582

5.  The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor.

Authors:  A J Vlot; S J Koppelman; M H van den Berg; B N Bouma; J J Sixma
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

6.  The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.

Authors:  R J Wise; A J Dorner; M Krane; D D Pittman; R J Kaufman
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

7.  Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction.

Authors:  P M Cacheris; W C Nichols; D Ginsburg
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

8.  Binding of factor VIII to von willebrand factor is enabled by cleavage of the von Willebrand factor propeptide and enhanced by formation of disulfide-linked multimers.

Authors:  A V Bendetowicz; J A Morris; R J Wise; G E Gilbert; R J Kaufman
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

9.  Kinetics of factor VIII-von Willebrand factor association.

Authors:  A J Vlot; S J Koppelman; J C Meijers; C Dama; H M van den Berg; B N Bouma; J J Sixma; G M Willems
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

10.  A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.

Authors:  E L Saenko; D Scandella
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

View more
  24 in total

1.  von Willebrand factor binds to the surface of dendritic cells and modulates peptide presentation of factor VIII.

Authors:  Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

2.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

3.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

4.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

5.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

6.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

Review 7.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

8.  The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Authors:  Ahmad H Mufti; Kenichi Ogiwara; Laura L Swystun; Jeroen C J Eikenboom; Ulrich Budde; Wilma M Hopman; Christer Halldén; Jenny Goudemand; Ian R Peake; Anne C Goodeve; David Lillicrap; Daniel J Hampshire
Journal:  Blood Adv       Date:  2018-07-10

9.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

10.  Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.

Authors:  Nadine Vollack-Hesse; Olga Oleshko; Sonja Werwitzke; Barbara Solecka-Witulska; Christoph Kannicht; Andreas Tiede
Journal:  Blood       Date:  2021-02-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.